We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pluristem Completes Enrollment in Phase I Hematology Study
Read MoreHide Full Article
Pluristem Therapeutics Inc. announced that it has completed patient enrollment in its phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), in the United States and Israel.
The multi-center, open-label, dose-escalating study will evaluate the safety of intramuscular injections of PLX-R18 cells in 20 subjects with incomplete hematopoietic recovery persisting for at least three months following HCT. The follow-up period is 12 months. Incomplete hematopoietic recovery poses a significant risk to HCT recipients who fail to respond to standard-of-care treatments, making them vulnerable to infections and bleeding.
Safety is the primary endpoint, with efficacy endpoints including changes in white blood cells, platelets counts, hemoglobin levels, changes in blood product requirements, and changes in quality of life. The company expects to report top-line efficacy results during the first quarter of 2021.
Shares of the company have soared 171.4% year to date compared with the industry’s growth of 2.7%.
Pluristem is a company that focuses on the development of placenta-based cell therapy products. Its patented PLX (PLacentaleXpanded) cells are being evaluated in multiple indications.
Zacks Rank & Stocks to Consider
Pluristem currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics Public Limited Company and Alimera Sciences Inc. (ALIM - Free Report) . While Emergent and Horizon Therapeutics sport a Zacks Rank #1 (Strong Buy), Alimera carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.45 to $5.60 for 2020 and from $3.73 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.86 for 2020 and from $2.72 to $4.29 for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Shutterstock
Pluristem Completes Enrollment in Phase I Hematology Study
Pluristem Therapeutics Inc. announced that it has completed patient enrollment in its phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), in the United States and Israel.
The multi-center, open-label, dose-escalating study will evaluate the safety of intramuscular injections of PLX-R18 cells in 20 subjects with incomplete hematopoietic recovery persisting for at least three months following HCT. The follow-up period is 12 months. Incomplete hematopoietic recovery poses a significant risk to HCT recipients who fail to respond to standard-of-care treatments, making them vulnerable to infections and bleeding.
Safety is the primary endpoint, with efficacy endpoints including changes in white blood cells, platelets counts, hemoglobin levels, changes in blood product requirements, and changes in quality of life. The company expects to report top-line efficacy results during the first quarter of 2021.
Shares of the company have soared 171.4% year to date compared with the industry’s growth of 2.7%.
Pluristem is a company that focuses on the development of placenta-based cell therapy products. Its patented PLX (PLacentaleXpanded) cells are being evaluated in multiple indications.
Zacks Rank & Stocks to Consider
Pluristem currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics Public Limited Company and Alimera Sciences Inc. (ALIM - Free Report) . While Emergent and Horizon Therapeutics sport a Zacks Rank #1 (Strong Buy), Alimera carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.45 to $5.60 for 2020 and from $3.73 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.86 for 2020 and from $2.72 to $4.29 for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.
Pluristem Therapeutics, Inc. Price
Pluristem Therapeutics, Inc. price | Pluristem Therapeutics, Inc. Quote
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>